New York, May 25, 2026, 14:02 EDT
- U.S. markets are closed for Memorial Day. Paysign ended Friday at $6.72.
- PAYS bounced back with five consecutive gains last week. Shares had tumbled after earnings.
- This week will test if investors still back the company’s move to patient affordability.
Paysign Inc. is up for a fifth straight session heading into the Memorial Day holiday, after shares bounced back from a rough earnings move earlier in the month. U.S. markets are closed Monday for Memorial Day, and Nasdaq notes May 25 as a non-trading day.
Paysign finished Friday at $6.72, rising 6.0% on the session. Shares are up roughly 19.6% from the May 15 close of $5.62, according to market data. This bounce comes after a 12.3% slide on May 13, right after Paysign posted first-quarter numbers. The stock then saw steady buying ahead of the holiday.
This stands out now, since the move far outperformed the wider market. The Nasdaq Composite was up 0.5% last week. The Russell 2000, which tracks small caps, added 2.7%, per Associated Press data.
Paysign’s Q2 targets are in focus for the shortened week that starts after Monday’s holiday. Investors are watching if the Friday close sticks. For Paysign, the question is whether its pharma unit keeps offsetting uneven plasma-center numbers and helps hit those second-quarter goals.
Paysign’s first-quarter revenue jumped 50.8% to $28.04 million. Net income was up sharply too, hitting $5.44 million, or 9 cents per diluted share. Pharma revenue posted the biggest gain, up 81.9% to $15.68 million, now making up the biggest part of the business ahead of plasma. Patient affordability programs support patients with drug costs.
Paysign CEO Mark Newcomer said the company got off to a “strong start to 2026” and said patient affordability now leads revenue. Paysign finished the quarter with 135 active patient affordability programs, up 45 net programs from a year earlier. Paysign, Inc.
Paysign CFO Jeff Baker said the company topped its targets on the income statement, backing confidence in the “upper half” of its full-year ranges. Paysign guided for second-quarter revenue between $26.2 million and $26.7 million and sees full-year 2026 revenue at $106.5 million to $110.5 million. The company forecasts full-year adjusted EBITDA between $30 million and $33 million, excluding interest, taxes, depreciation, amortization and stock-based comp.
Lake Street Capital Markets’ Jacob Stephan asked Paysign’s management on the earnings call if new programs were from new clients or existing ones. Matt Turner, president of patient affordability, said it’s about half and half. “Selling never stops,” he said.
Paysign’s plasma business is mixed. Plasma revenue was up 24.9% to $11.75 million for the first quarter. But active plasma centers are expected to drop to 555-560 by the end of the second quarter after some customer centers closed, down from 573 at the end of Q1.
Baker told analysts the company is looking for plasma revenue to rise quarter over quarter for the rest of the year, despite closing some centers that haven’t met targets. But traders are likely to focus on the drop in center count if the stock pulls back.
Paysign’s competitive setup isn’t balanced. It doesn’t match up with bigger merchant processors like Fiserv or Global Payments, who are in the business of selling payments and commerce tech at scale. Paysign also isn’t only a benefits account operator such as WEX, known for managing HSAs, FSAs, HRAs and similar plans. Instead, Paysign is mainly about pharma assistance, paying plasma donors, and running payment flows for life sciences.
Paysign says the trade carries downside. The company flagged that growth might ease up, that new patient affordability programs may take longer, not show up, or could drop off. Plasma clients might leave for other providers or shut down locations. Regulatory changes on copay help could hit results. The newer software project is still with the FDA and isn’t bringing in sales right now, Newcomer said on the call with Jon Hickman at Ladenburg Thalmann.
Paysign goes into Tuesday’s session with a firmer footing than it showed right after earnings. Now traders will watch to see if this rebound is just a holiday-week squeeze or if the market is betting on a more lasting shift for its pharma payments business.
